A comprehensive approach to support people and parents living with eczema

While eczema is one of the most common skin conditions, it remains one of the most challenging to live with. Eczema is a chronic (long lasting) condition without a cure. It’s also unique for each person — including symptoms, severity and which treatments may help. Thus, managing eczema can be complex journey based off individual needs. Finding effective treatments can be hard. Finding trusted information can be hard. Chances to engage in research or let your voice be heard can be few.

At OHSU we've launched an initiative with the goal of eliminating some of these challenges that can come from living with eczema. The CLEAR Eczema Center is collection of efforts designed to better support the eczema community in clinical care, lifestyle, education, advocacy and research. We're looking to build upon a legacy of researching and treating eczema at OHSU, with a more comprehensive and easily accessible group of resources available to those with eczema. We hope you can join us as we continue to build these resources, joining with a common goal of reducing the effects eczema has on individuals worldwide.

Clinical care

An icon representing clinical care


An icon of a spinning globe representing research


An icon of a book representing education

About us

An icon representing our About Us page

Event: Eczema and Food Allergies

Common allergens being looked at under a magnifying glass

Date: Saturday, March 16, 2024
Time: 10 a.m. - 1 p.m.
Location: Rood Family Pavilion (or virtual)

A free event for adults, children, and families living with eczema: Experts will present the latest research on food allergies and their connection with eczema, including recommendations on living a healthy lifestyle with eczema. Allergy friendly lunch provided!


Clinical care/appointments: 503-418-3376

Clinical research participation: 503-418-9386 or dermtrials@ohsu.edu

General inquiries: kinghopa@ohsu.edu

News highlight

Sept. 2021:  FDA approves topical ruxolitinib for atopic dermatitis, first JAK inhibitor for this indication in the U.S.
The first topical JAK inhibitor approved for AD for mild to moderate atopic dermatitis ages 12 years and older– and the first JAK inhibitor approved for this indication – in the United States.

"What is Eczema?" educational video

An animated overview on eczema, including its causes, symptoms, side effects and management

5 Tips to Improve Your Eczema

An animated overview on key tips to help you manage and improve your atopic dermatitis, also known as eczema.